TrueMark Investments LLC Invests $609,000 in Guardant Health, Inc. $GH

TrueMark Investments LLC purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,596 shares of the company’s stock, valued at approximately $609,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GH. Erste Asset Management GmbH boosted its position in shares of Guardant Health by 10.4% during the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares during the last quarter. World Investment Advisors acquired a new stake in Guardant Health during the fourth quarter worth about $1,664,000. Segall Bryant & Hamill LLC increased its position in Guardant Health by 57.8% during the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after purchasing an additional 111,822 shares during the last quarter. TD Asset Management Inc raised its stake in Guardant Health by 16.1% during the third quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock worth $11,797,000 after purchasing an additional 26,210 shares during the period. Finally, Algert Global LLC raised its stake in Guardant Health by 169.1% during the third quarter. Algert Global LLC now owns 120,114 shares of the company’s stock worth $7,505,000 after purchasing an additional 75,474 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GH has been the subject of several research analyst reports. Wolfe Research assumed coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price for the company. Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target on the stock in a research note on Tuesday, June 2nd. UBS Group set a $150.00 price objective on shares of Guardant Health in a report on Wednesday. BTIG Research set a $160.00 price objective on shares of Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, May 27th. Finally, Piper Sandler set a $127.00 price objective on shares of Guardant Health in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $142.19.

Insider Buying and Selling

In other news, Director Myrtle S. Potter sold 1,556 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $204,084.96. Following the completion of the transaction, the director directly owned 20,971 shares of the company’s stock, valued at approximately $2,750,556.36. The trade was a 6.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Steve E. Krognes sold 9,294 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $132.51, for a total transaction of $1,231,547.94. Following the sale, the director owned 10,222 shares in the company, valued at $1,354,517.22. The trade was a 47.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 452,513 shares of company stock worth $51,608,916 over the last ninety days. Company insiders own 5.60% of the company’s stock.

Guardant Health Trading Up 4.7%

Shares of NASDAQ GH opened at $136.96 on Thursday. The stock has a market cap of $18.16 billion, a P/E ratio of -40.40 and a beta of 1.61. The business’s fifty day simple moving average is $110.21 and its 200-day simple moving average is $103.42. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $141.07.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.